Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Netazepide - Trio Medicines

Drug Profile

Netazepide - Trio Medicines

Alternative Names: sograzepide; YF 476

Latest Information Update: 27 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma; Trio Medicines
  • Developer Ferring Pharmaceuticals; Trio Medicines
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cholecystokinin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Barrett's oesophagus; Neuroendocrine tumours
  • Discontinued Gastro-oesophageal reflux; Peptic ulcer; Reflux oesophagitis

Most Recent Events

  • 14 Aug 2019 Trio Medicines terminates a phase II trial due to poor recruitment in Neuroendocrine tumours (Gastric carcinoids) in USA (PO) (NCT02454075)
  • 24 Jun 2018 Biomarkers information updated
  • 29 Jan 2018 Netazepide is still in phase II trials for Barrett's oesophagus in USA and United Kingdom (NCT01298999)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top